Smith & Nephew SNATS (NYSE:SNN) Raised to Strong-Buy at Wall Street Zen

Smith & Nephew SNATS (NYSE:SNN) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Sunday.

Several other research analysts also recently commented on the stock. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Smith & Nephew SNATS in a report on Monday, October 20th. Sanford C. Bernstein set a $37.50 price target on Smith & Nephew SNATS and gave the stock a “market perform” rating in a report on Tuesday, October 14th. Finally, Canaccord Genuity Group reduced their price objective on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Smith & Nephew SNATS presently has an average rating of “Hold” and an average target price of $35.75.

Smith & Nephew SNATS Price Performance

Shares of SNN opened at $32.61 on Friday. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a fifty-two week low of $23.69 and a fifty-two week high of $38.79. The business’s 50-day moving average is $34.43 and its two-hundred day moving average is $33.68.

Hedge Funds Weigh In On Smith & Nephew SNATS

Institutional investors and hedge funds have recently bought and sold shares of the business. Cetera Investment Advisers raised its holdings in Smith & Nephew SNATS by 8.9% during the 1st quarter. Cetera Investment Advisers now owns 16,748 shares of the medical equipment provider’s stock worth $475,000 after purchasing an additional 1,373 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Smith & Nephew SNATS by 8.8% during the first quarter. PNC Financial Services Group Inc. now owns 9,923 shares of the medical equipment provider’s stock worth $282,000 after buying an additional 803 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Smith & Nephew SNATS by 7.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 35,890 shares of the medical equipment provider’s stock valued at $1,018,000 after buying an additional 2,585 shares during the period. Russell Investments Group Ltd. boosted its stake in Smith & Nephew SNATS by 20.4% in the first quarter. Russell Investments Group Ltd. now owns 283,483 shares of the medical equipment provider’s stock valued at $8,042,000 after acquiring an additional 48,043 shares during the last quarter. Finally, Boston Partners grew its holdings in Smith & Nephew SNATS by 44.8% during the 1st quarter. Boston Partners now owns 129,893 shares of the medical equipment provider’s stock worth $3,685,000 after acquiring an additional 40,211 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.